View Financial HealthHydration Pharmaceuticals 배당 및 자사주 매입배당 기준 점검 0/6Hydration Pharmaceuticals 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-55.0%자사주 매입 수익률총 주주 수익률-55.0%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • Jun 25New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 38% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Market cap is less than US$10m (AU$2.64m market cap, or US$1.83m). Minor Risk Revenue is less than US$5m (US$2.5m revenue).공시 • Jun 23The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.392 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.392 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 98,000,000 Price\Range: AUD 0.004 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Jun 16The Hydration Pharmaceuticals Company Limited Announces Board ChangesThe Hydration Pharmaceuticals Company Limited appointed George Karafotias and Nick Katiforis as Non-Executive Directors, effective June 16, 2026. The Company advised that Adem Karafili and Joseph Constable resigned as Non-Executive Chair and Non-Executive Director respectively, effective on the appointment of Mr. Karafotias and Mr. Katiforis. Nick Berry assumed the role of Non-Executive Chair. George Karafotias is a specialist in restructuring, reinventing and implementing turnaround strategies for various ASX-listed companies with great success. His extensive experience includes an established track record with publicly-traded businesses, predominantly in senior executive positions. He holds a Bachelor of Commerce degree from the University of Adelaide. Nick Katiforis is a financial services professional with over 20 years’ experience across capital markets, equities, options and FX. He has been a Director of Futurity Trading, a financial services and trading firm, since 2000 and holds ASIC financial adviser accreditation. He brings extensive experience in client engagement, execution, capital markets distribution and regulatory compliance.공시 • Jun 15The Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.392 million.The Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.392 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 98,000,000 Price\Range: AUD 0.004 Security Features: Attached Options Transaction Features: Subsequent Direct ListingBoard Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Joseph Constable was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Apr 30The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 29, 2026The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 29, 2026.공시 • Jul 10The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.608879 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.608879 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 13,387,853 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,000,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 39,500,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,000,000 Price\Range: AUD 0.01 Transaction Features: Rights Offering공시 • Mar 25The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.65 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.65 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 65,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct Listing공시 • Mar 18+ 1 more updateThe Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.609826 million.The Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.609826 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 60,982,614 Price\Range: AUD 0.01 Transaction Features: Rights Offering공시 • Mar 14The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 28, 2025The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 28, 2025.Board Change • Sep 03Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Margaret Hardin was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • May 29Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Margaret Hardin was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • May 24The Hydration Pharmaceuticals Company Limited Announces Board Change, Effective 25 May 2024The Hydration Pharmaceuticals Company Limited announced that further to the change of Board composition announced on 23 April 2024, and as part of the Company's continuous review of Board skills and composition, Mr. Nick Berry will be appointed as a non-executive Director, effective 25 May 2024. Mr. Nick Berry's appointment as non-executive director will be effective following the resignation of Mr. George Livery on 25 May 2024. Nick Berry brings over 19 years of experience in the Australian finance industry, specialising in equity and debt capital markets, mergers and acquisitions and strategic planning. With a proven track record in raising capital and structuring and negotiating complex financial transactions, Nick has demonstrated extensive expertise and leadership in the field. He previously served as an Executive Director at Nomura Australia and is currently a Director of PURE Asset Management Pty Ltd. Nick holds a Master of Engineering (MEng) from the University of Bath and is a Member of the Australian Institute of Company Directors.Reported Earnings • Mar 01Full year 2023 earnings released: US$0.04 loss per share (vs US$0.065 loss in FY 2022)Full year 2023 results: US$0.04 loss per share (improved from US$0.065 loss in FY 2022). Revenue: US$10.0m (up 10% from FY 2022). Net loss: US$8.10m (loss narrowed 24% from FY 2022).New Risk • Mar 01New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$358k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.7m free cash flow). Shares are highly illiquid. Negative equity (-US$358k). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Market cap is less than US$10m (AU$4.24m market cap, or US$2.76m).공시 • Feb 22The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 07, 2024The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 07, 2024.New Risk • Sep 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 56% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.3m free cash flow). Shares are highly illiquid. Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Market cap is less than US$10m (AU$9.97m market cap, or US$6.40m).Reported Earnings • Sep 05First half 2023 earnings released: US$0.022 loss per share (vs US$0.026 loss in 1H 2022)First half 2023 results: US$0.022 loss per share (improved from US$0.026 loss in 1H 2022). Revenue: US$5.30m (up 28% from 1H 2022). Net loss: US$3.53m (loss narrowed 17% from 1H 2022).공시 • Aug 29The Hydration Pharmaceuticals Company Limited Announces Resignation of Gretta van Riel as Non-Executive Director, Effective September 26, 2023The Hydration Pharmaceuticals Company Limited announced that Ms. Gretta van Riel has resigned as a Non-Executive Director of the Company, effective from the 26th of September.New Risk • Aug 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 21% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.8m free cash flow). Shares are highly illiquid. Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (AU$7.12m market cap, or US$4.62m). Minor Risk Shareholders have been diluted in the past year (21% increase in shares outstanding).공시 • Aug 12The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 33,333,337 Price\Range: AUD 0.045 Discount Per Security: AUD 0.0027 Security Features: Attached Options Transaction Features: Subsequent Direct ListingReported Earnings • Mar 01Full year 2022 earnings released: US$0.07 loss per share (vs US$0.12 loss in FY 2021)Full year 2022 results: US$0.07 loss per share. Revenue: US$9.10m (up 49% from FY 2021). Net loss: US$10.6m (loss widened 19% from FY 2021).공시 • Feb 08The Hydration Pharmaceuticals Company Limited Announces Executive ChangesThe Hydration Pharmaceuticals Company Limited announced the appointment of Victoria Nadalin as Company Secretary upon the resignation of Carlie Hodges, effective 8 February 2023. Victoria is a practising corporate and commercial lawyer and is completing a Graduate Diploma in Applied Corporate Governance and Risk Management with the Governance Institute of Australia.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 HPC 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: HPC 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Hydration Pharmaceuticals 배당 수익률 vs 시장HPC의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (HPC)n/a시장 하위 25% (AU)2.7%시장 상위 25% (AU)6.7%업계 평균 (Personal Products)2.5%분석가 예측 (HPC) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 HPC 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 HPC 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 HPC 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: HPC 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YAU 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/06 17:20종가2026/06/29 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스The Hydration Pharmaceuticals Company Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
New Risk • Jun 25New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 38% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Market cap is less than US$10m (AU$2.64m market cap, or US$1.83m). Minor Risk Revenue is less than US$5m (US$2.5m revenue).
공시 • Jun 23The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.392 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.392 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 98,000,000 Price\Range: AUD 0.004 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Jun 16The Hydration Pharmaceuticals Company Limited Announces Board ChangesThe Hydration Pharmaceuticals Company Limited appointed George Karafotias and Nick Katiforis as Non-Executive Directors, effective June 16, 2026. The Company advised that Adem Karafili and Joseph Constable resigned as Non-Executive Chair and Non-Executive Director respectively, effective on the appointment of Mr. Karafotias and Mr. Katiforis. Nick Berry assumed the role of Non-Executive Chair. George Karafotias is a specialist in restructuring, reinventing and implementing turnaround strategies for various ASX-listed companies with great success. His extensive experience includes an established track record with publicly-traded businesses, predominantly in senior executive positions. He holds a Bachelor of Commerce degree from the University of Adelaide. Nick Katiforis is a financial services professional with over 20 years’ experience across capital markets, equities, options and FX. He has been a Director of Futurity Trading, a financial services and trading firm, since 2000 and holds ASIC financial adviser accreditation. He brings extensive experience in client engagement, execution, capital markets distribution and regulatory compliance.
공시 • Jun 15The Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.392 million.The Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.392 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 98,000,000 Price\Range: AUD 0.004 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Joseph Constable was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Apr 30The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 29, 2026The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 29, 2026.
공시 • Jul 10The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.608879 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.608879 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 13,387,853 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,000,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 39,500,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,000,000 Price\Range: AUD 0.01 Transaction Features: Rights Offering
공시 • Mar 25The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.65 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.65 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 65,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct Listing
공시 • Mar 18+ 1 more updateThe Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.609826 million.The Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.609826 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 60,982,614 Price\Range: AUD 0.01 Transaction Features: Rights Offering
공시 • Mar 14The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 28, 2025The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 28, 2025.
Board Change • Sep 03Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Margaret Hardin was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • May 29Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Margaret Hardin was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • May 24The Hydration Pharmaceuticals Company Limited Announces Board Change, Effective 25 May 2024The Hydration Pharmaceuticals Company Limited announced that further to the change of Board composition announced on 23 April 2024, and as part of the Company's continuous review of Board skills and composition, Mr. Nick Berry will be appointed as a non-executive Director, effective 25 May 2024. Mr. Nick Berry's appointment as non-executive director will be effective following the resignation of Mr. George Livery on 25 May 2024. Nick Berry brings over 19 years of experience in the Australian finance industry, specialising in equity and debt capital markets, mergers and acquisitions and strategic planning. With a proven track record in raising capital and structuring and negotiating complex financial transactions, Nick has demonstrated extensive expertise and leadership in the field. He previously served as an Executive Director at Nomura Australia and is currently a Director of PURE Asset Management Pty Ltd. Nick holds a Master of Engineering (MEng) from the University of Bath and is a Member of the Australian Institute of Company Directors.
Reported Earnings • Mar 01Full year 2023 earnings released: US$0.04 loss per share (vs US$0.065 loss in FY 2022)Full year 2023 results: US$0.04 loss per share (improved from US$0.065 loss in FY 2022). Revenue: US$10.0m (up 10% from FY 2022). Net loss: US$8.10m (loss narrowed 24% from FY 2022).
New Risk • Mar 01New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$358k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.7m free cash flow). Shares are highly illiquid. Negative equity (-US$358k). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Market cap is less than US$10m (AU$4.24m market cap, or US$2.76m).
공시 • Feb 22The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 07, 2024The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 07, 2024.
New Risk • Sep 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 56% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.3m free cash flow). Shares are highly illiquid. Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Market cap is less than US$10m (AU$9.97m market cap, or US$6.40m).
Reported Earnings • Sep 05First half 2023 earnings released: US$0.022 loss per share (vs US$0.026 loss in 1H 2022)First half 2023 results: US$0.022 loss per share (improved from US$0.026 loss in 1H 2022). Revenue: US$5.30m (up 28% from 1H 2022). Net loss: US$3.53m (loss narrowed 17% from 1H 2022).
공시 • Aug 29The Hydration Pharmaceuticals Company Limited Announces Resignation of Gretta van Riel as Non-Executive Director, Effective September 26, 2023The Hydration Pharmaceuticals Company Limited announced that Ms. Gretta van Riel has resigned as a Non-Executive Director of the Company, effective from the 26th of September.
New Risk • Aug 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 21% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.8m free cash flow). Shares are highly illiquid. Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (AU$7.12m market cap, or US$4.62m). Minor Risk Shareholders have been diluted in the past year (21% increase in shares outstanding).
공시 • Aug 12The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 33,333,337 Price\Range: AUD 0.045 Discount Per Security: AUD 0.0027 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
Reported Earnings • Mar 01Full year 2022 earnings released: US$0.07 loss per share (vs US$0.12 loss in FY 2021)Full year 2022 results: US$0.07 loss per share. Revenue: US$9.10m (up 49% from FY 2021). Net loss: US$10.6m (loss widened 19% from FY 2021).
공시 • Feb 08The Hydration Pharmaceuticals Company Limited Announces Executive ChangesThe Hydration Pharmaceuticals Company Limited announced the appointment of Victoria Nadalin as Company Secretary upon the resignation of Carlie Hodges, effective 8 February 2023. Victoria is a practising corporate and commercial lawyer and is completing a Graduate Diploma in Applied Corporate Governance and Risk Management with the Governance Institute of Australia.